2001The Chinese Journal of Clinical PharmacologyRequires access

Study on in vitro Antibacterial Activity of Cefperazone/Tazobactam

Hu Yun

Open publisher page 0 citations

Abstract

OBJECTIVE: The antibacterial activity in vitro of cefperazone/tazobactam was evaluated. METHODS: Cefperazone/tazobactam (4:1) against 601 clinical isolated strains was compared with cefperazone, tazobactam, cefperazone/sulbactam, piperacillinltazobactam and impipenenilceilastatin. Minimal inhibitory concentrations (MIC) were measured by agar dilution method and minimal bactericidal concentrations (MBC) were measured by broth dilution method. RESULTS: The antibacterial activity of cefperazone/tazobactam (4:1), the MIC50 and MIC90 against the strains producing extended spectrum b-lactamases (ESBLs) were 32-64 times and 16-32 times lower than cefperazone and were 2 times and 4 times lower than cefperazone/sulbactam and piperacillin/tazobactam. The bactericidal activity of cefperazone/tazobactam is better than cefperazone and similar as cefperazone/ sulbactam (1:1) and piperacillin/tazobactam (8:1). The inoculum size, pH and concentration of serum protein did not influence the in vitro the activity of cefperazone/tazobatam (4:1). CONCLUSION: Cefperazone/tazobactam (4:1) is an effective antibiotic containing β-lactamases inhibitor and valuable to be investigated.

About this research paper

What this paper is about

OBJECTIVE: The antibacterial activity in vitro of cefperazone/tazobactam was evaluated. METHODS: Cefperazone/tazobactam (4:1) against 601 clinical isolated strains was compared with cefperazone, tazobactam, cefperazone/sulbactam, piperacillinltazobactam and impipenenilceilastatin. Minimal inhibitory concentrations (MIC) were measured by agar dilution method and minimal bactericidal concentrations (MBC) were measured by broth dilution method. RESULTS: The antibacterial activity of cefperazone/tazobactam (4:1), the MIC50 and MIC90 against the strains producing extended spectrum b-lactamases (ESBLs) were 32-64 times and 16-32 times lower than cefperazone and were 2 times and 4 times lower than cefperazone/sulbactam and piperacillin/tazobactam. The bactericidal activity of cefperazone/tazobactam is better than cefperazone and similar as cefperazone/ sulbactam (1:1) and piperacillin/tazobactam (8:1). The inoculum size, pH and concentration of serum protein did not influence the in vitro the activity of cefperazone/tazobatam (4:1). CONCLUSION: Cefperazone/tazobactam (4:1) is an effective antibiotic containing β-lactamases inhibitor and valuable to be investigated.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: The antibacterial activity in vitro of cefperazone/tazobactam was evaluated. METHODS: Cefperazone/tazobactam (4:1) against 601 clinical isolated strains was compared with cefperazone, tazobactam, cefperazone/sulbactam, piperacillinltazobactam and impipenenilceilastatin. Minimal inhibitory concentrations (MIC) were measured by agar dilution method and minimal bactericidal concentrations (MBC) were measured by broth dilution method. RESULTS: The antibacterial activity of cefperazone/tazobactam (4:1), the MIC50 and MIC90 against the strains producing extended spectrum b-lactamases (ESBLs) were 32-64 times and 16-32 times lower than cefperazone and were 2 times and 4 times lower than cefperazone/sulbactam and piperacillin/tazobactam. The bactericidal activity of cefperazone/tazobactam is better than cefperazone and similar as cefperazone/ sulbactam (1:1) and piperacillin/tazobactam (8:1). The inoculum size, pH and concentration of serum protein did not influence the in vitro the activity of cefperazone/tazobatam (4:1). CONCLUSION: Cefperazone/tazobactam (4:1) is an effective antibiotic containing β-lactamases inhibitor and valuable to be investigated.

Key concepts: Sulbactam, Tazobactam, Piperacillin/tazobactam, Agar Dilution Method, Antibacterial activity, Piperacillin, Minimum inhibitory concentration, Agar dilution

Related papers

Back to paper searchBrowse research topicsOriginal source
Study on in vitro Antibacterial Activity of Cefperazone/Tazobactam — Research Paper | ScholarLens